drugset / Trial / NCT01893125

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy

NCT01893125 ↗

Phase 2 Completed 126 enrolled Convergence Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in diabetic peripheral neuropathy (DPN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.

Timeline

Start
2013-08
Primary completion
2014-06
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CNV2197944 Small molecule 75 mg Oral